New patient-derived models of castrate-sensitive and castrate-resistant prostate cancer

Mitchell Lawrence; David Clouston; Mark Frydenberg; Declan G Murphy; Carmel Jo Pezaro; David William Pook; Heather Thorne; Shahneen Kaur Sandhu; Roxanne Toivanen; Renea Taylor; Gail Risbridger

Conference Proceedings

New patient-derived models of castrate-sensitive and castrate-resistant prostate cancer

Mitchell Lawrence, David Clouston, Mark Frydenberg, Declan G Murphy, Carmel Jo Pezaro, David William Pook, Heather Thorne, Shahneen Kaur Sandhu, Roxanne Toivanen, Renea Taylor, Gail Risbridger

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2020

DOI: 10.1200/jco.2020.38.6_suppl.151

Abstract

151 Background: There are fewer preclinical models of prostate cancer compared to other common tumours. New models that represent the diverse features of castrate-sensitive and castration-resistant prostate cancer (CRPC) are required for thorough preclinical testing of novel treatments. Therefore, the goal of the Melbourne Urological Research Alliance (MURAL) is to develop patient-derived xenografts (PDXs) spanning the clinical trajectory of prostate cancer. Methods: We grafted >200 surgery, biopsy or rapid autopsy samples into testosterone-supplemented or castrated male NSG mice. Actively growing tumours were serially transplanted or grown as explants or organoids. PDXs were analysed using..

View full abstract

University of Melbourne Researchers

Mitchell Lawrence Author

Declan Murphy Author

Renea Taylor Author

Grants

Funding Acknowledgements

[ "Australian National Health and Medical Research Council.", "Victorian Cancer Agency, EJ Whitten Foundation, Movember, Endocrine Society of Australia, CASS Foundation." ]